At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 16 enrolled
Drug / intervention
Polidocanol Endovenous Microfoam 0.125%drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Single-dose Pilot Study to Evaluate the Efficacy and Safety of Varisolve® (Polidocanol Endovenous Microfoam) 0.125% [0.2%] for the Treatment of Symptomatic, Visible Varicose Veins With Saphenofemoral Junction (SFJ) Incompetence
In Brief
A Phase 2 clinical trial evaluating Polidocanol Endovenous Microfoam 0.125% for Varicose Veins. Completed, enrolled 16 participants across 1 site.
Detailed Summary
To determine the effect and safety of Varisolve® 0.125% \[0.2%\]
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVaricose Veins
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2009
First PostedJun 2009
Primary CompletionDec 2009
Study CompletionJan 2010
TodayJul 2026
First PostedJun 26, 2009
Enrollment StartJun 1, 2009
Primary CompletionDec 1, 2009
Study CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 17.0 years ago
Interventions
Polidocanol Endovenous Microfoam 0.125%drug
Polidocanol Endovenous Microfoam 0.125%, single dose